What is Jaguar Health Inc's earnings per share (EPS)?

Jaguar Health Inc (JAGX) reported diluted earnings per share of $-22.97 for fiscal year 2025. This represents a -17474.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Jaguar Health Inc Financials

JAGX

Source SEC Filings (10-K/10-Q) Updated Apr 7, 2026 Currency USD FYE April

This page shows Jaguar Health Inc (JAGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 8/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Jaguar Health Inc has an operating margin of -404.9%, meaning the company retains $-405 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -263.8% the prior year.

Growth

Jaguar Health Inc's revenue declined 3% year-over-year, from $11.7M to $11.3M. This contraction results in a growth score of 28/100.

Liquidity

Jaguar Health Inc's current ratio of 0.50 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 4/100, which could limit financial flexibility.

Cash Flow

While Jaguar Health Inc generated -$23.7M in operating cash flow, capex of $16K consumed most of it, leaving -$23.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Piotroski F-Score Weak

3/9

Jaguar Health Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.44x

For every $1 of reported earnings, Jaguar Health Inc generates $0.44 in operating cash flow (-$23.7M OCF vs -$53.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-685.2x

Jaguar Health Inc earns $-685.2 in operating income for every $1 of interest expense (-$45.9M vs $67K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.3M

YoY-3.0%

5Y CAGR+3.9%

10Y CAGR+46.0%

Jaguar Health Inc generated $11.3M in revenue in fiscal year 2025. This represents a decrease of 3.0% from the prior year.

EBITDA

-$44.0M

YoY-52.1%

Jaguar Health Inc's EBITDA was -$44.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 52.1% from the prior year.

Net Income

-$53.6M

YoY-136396.8%

Jaguar Health Inc reported -$53.6M in net income in fiscal year 2025. This represents a decrease of 136396.8% from the prior year.

EPS (Diluted)

$-22.97

YoY-17474.6%

Jaguar Health Inc earned $-22.97 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 17474.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$23.7M

YoY+19.4%

Jaguar Health Inc generated -$23.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 19.4% from the prior year.

Cash & Debt

$968K

YoY-87.9%

5Y CAGR-34.6%

10Y CAGR-18.7%

Jaguar Health Inc held $968K in cash against $52K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

13M

10Y CAGR+4.8%

Jaguar Health Inc had 13M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

99.1%

YoY+15.9pp

5Y CAGR+34.1pp

10Y CAGR+46.9pp

Jaguar Health Inc's gross margin was 99.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 15.9 percentage points from the prior year.

Operating Margin

-404.9%

YoY-141.1pp

5Y CAGR-120.9pp

10Y CAGR+4411.8pp

Jaguar Health Inc's operating margin was -404.9% in fiscal year 2025, reflecting core business profitability. This is down 141.1 percentage points from the prior year.

Net Margin

-472.5%

YoY-472.1pp

5Y CAGR-112.2pp

10Y CAGR+5832.8pp

Jaguar Health Inc's net profit margin was -472.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 472.1 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$25.0M

YoY+50.9%

5Y CAGR+31.2%

10Y CAGR+14.4%

Jaguar Health Inc invested $25.0M in research and development in fiscal year 2025. This represents an increase of 50.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$16K

YoY+0.0%

5Y CAGR+18.0%

10Y CAGR-3.7%

Jaguar Health Inc invested $16K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

JAGX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$11.3M-3.0%	$11.7M+19.8%	$9.8M-18.4%	$12.0M+175.8%	$4.3M-53.8%	$9.4M
Cost of Revenue	$97K-95.0%	$2.0M-4.0%	$2.0M+0.9%	$2.0M-13.5%	$2.3M-28.9%	$3.3M
Gross Profit	$11.2M+15.5%	$9.7M+26.0%	$7.7M-22.3%	$9.9M+396.4%	$2.0M-67.2%	$6.1M
R&D Expenses	$25.0M+50.9%	$16.5M-11.0%	$18.6M+5.4%	$17.6M+17.0%	$15.1M+135.1%	$6.4M
SG&A Expenses	$18.6M+14.2%	$16.3M-1.5%	$16.6M-7.2%	$17.9M+4.5%	$17.1M+18.9%	$14.4M
Operating Income	-$45.9M-48.9%	-$30.8M+10.1%	-$34.3M+0.4%	-$34.4M+15.5%	-$40.7M-52.8%	-$26.6M
Interest Expense	$67K-71.0%	$231K-96.4%	$6.4M-49.8%	$12.7M+51.1%	$8.4M+201.6%	$2.8M
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$53.6M-136396.8%	-$39K+6.3%	-$42K+13.4%	-$48K+8.0%	-$53K+99.8%	-$33.8M
EPS (Diluted)	$-22.97-17474.6%	$-0.13+95.1%	$-2.68-7298.3%	$-0.04+59.0%	$-0.09+97.1%	$-3.00

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$3.1M+3.5%	$3.0M+34.6%	$2.2M-36.9%	$3.5M+12.9%	$3.1M+14.2%	$2.7M+15.7%	$2.4M	N/A
Cost of Revenue	$532K+448.5%	$97K-81.2%	$515K-7.5%	$557K+3.0%	$541K+26.7%	$427K-0.7%	$430K	N/A
Gross Profit	$2.6M-11.5%	$2.9M+69.6%	$1.7M-42.4%	$3.0M+15.0%	$2.6M+11.9%	$2.3M+19.4%	$1.9M	N/A
R&D Expenses	$3.7M+12.0%	$3.3M-12.5%	$3.7M-17.7%	$4.5M+12.1%	$4.0M+10.7%	$3.7M-15.3%	$4.3M	N/A
SG&A Expenses	$4.1M-12.5%	$4.7M-3.5%	$4.9M+26.9%	$3.9M+2.2%	$3.8M-12.5%	$4.3M-1.5%	$4.4M	N/A
Operating Income	-$7.2M+9.6%	-$8.0M+15.0%	-$9.4M-15.5%	-$8.2M-12.3%	-$7.3M-0.9%	-$7.2M+12.4%	-$8.2M	N/A
Interest Expense	$6K+140.0%	-$15K+73.2%	-$56K+49.1%	-$110K+32.1%	-$162K-50.0%	-$108K-117.7%	$611K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	N/A
Net Income	-$9.5M+8.7%	-$10.4M+0.5%	-$10.5M-136.7%	$28.5M+389.6%	-$9.9M-3.8%	-$9.5M-2.9%	-$9.2M	N/A
EPS (Diluted)	$-6.28+38.8%	$-10.26+38.6%	$-16.70	N/A	$-26.29-888.3%	$-2.66+96.9%	$-87.12	N/A

JAGX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$38.3M-28.3%	$53.4M+5.2%	$50.8M+7.0%	$47.5M-10.9%	$53.3M+24.3%	$42.8M
Current Assets	$20.3M-36.8%	$32.2M+15.1%	$28.0M+25.3%	$22.3M-21.5%	$28.4M+59.8%	$17.8M
Cash & Equivalents	$968K-87.9%	$8.0M+23.7%	$6.5M+18.3%	$5.5M-67.9%	$17.1M+110.8%	$8.1M
Inventory	$8.6M-16.9%	$10.3M+12.6%	$9.2M+30.8%	$7.0M+43.3%	$4.9M+76.1%	$2.8M
Accounts Receivable	$1.5M-0.4%	$1.5M-22.4%	$2.0M+4.7%	$1.9M+9.9%	$1.7M-18.5%	$2.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$57.0M+28.3%	$44.4M-3.1%	$45.9M-6.0%	$48.8M+17.9%	$41.4M+61.5%	$25.6M
Current Liabilities	$40.7M+106.3%	$19.7M+40.9%	$14.0M-53.9%	$30.3M+96.1%	$15.5M+17.0%	$13.2M
Long-Term Debt	$52K	N/A	N/A	N/A	N/A	N/A
Total Equity	-$18.7M-387.8%	$6.5M+32.6%	$4.9M+460.3%	-$1.4M-111.5%	$11.9M-31.1%	$17.2M
Retained Earnings	-$399.9M-15.4%	-$346.5M-12.4%	-$308.2M-15.5%	-$266.9M-21.6%	-$219.5M-31.5%	-$166.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$49.5M+2.5%	$48.3M-6.2%	$51.5M-3.7%	$53.4M-8.6%	$58.5M-4.9%	$61.5M+11.0%	$55.4M+9.1%	$50.8M
Current Assets	$29.4M+5.4%	$27.9M-8.3%	$30.4M-5.5%	$32.2M-12.1%	$36.6M-8.6%	$40.1M+19.0%	$33.7M+20.6%	$28.0M
Cash & Equivalents	$3.5M+59.8%	$2.2M-61.2%	$5.7M-28.9%	$8.0M-39.7%	$13.3M-17.3%	$16.0M+37.5%	$11.7M+80.4%	$6.5M
Inventory	$10.6M-0.8%	$10.7M+1.6%	$10.6M+2.0%	$10.3M+6.9%	$9.7M+1.2%	$9.6M+5.9%	$9.0M-1.8%	$9.2M
Accounts Receivable	$1.4M+22.5%	$1.2M-4.1%	$1.2M-19.9%	$1.5M+22.3%	$1.2M-3.8%	$1.3M-14.1%	$1.5M-23.1%	$2.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$45.1M+9.0%	$41.4M-14.0%	$48.1M+8.3%	$44.4M+3.6%	$42.9M+1.1%	$42.4M+3.2%	$41.1M-10.4%	$45.9M
Current Liabilities	$36.1M+23.6%	$29.2M+3.6%	$28.2M+43.2%	$19.7M-0.9%	$19.9M+3.9%	$19.1M+7.4%	$17.8M+27.4%	$14.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.4M-36.6%	$6.9M+728.9%	$830K-87.2%	$6.5M-50.4%	$13.1M-21.0%	$16.6M+40.3%	$11.8M+141.4%	$4.9M
Retained Earnings	-$376.9M-2.6%	-$367.4M-2.9%	-$356.9M-3.0%	-$346.5M-2.9%	-$336.6M-3.0%	-$326.7M-3.0%	-$317.2M-2.9%	-$308.2M

JAGX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$23.7M+19.4%	-$29.4M+11.6%	-$33.2M-0.4%	-$33.1M+5.3%	-$35.0M-128.9%	-$15.3M
Capital Expenditures	$16K0.0%	$16K	N/A	$77K+1183.3%	$6K-14.3%	$7K
Free Cash Flow	-$23.7M+19.4%	-$29.4M	N/A	-$33.2M+5.1%	-$35.0M-128.8%	-$15.3M
Investing Cash Flow	-$41K+82.3%	-$231K	N/A	-$1.7M-27816.7%	-$6K+14.3%	-$7K
Financing Cash Flow	$23.7M-24.1%	$31.2M-8.8%	$34.2M+47.7%	$23.2M-47.2%	$43.9M+125.4%	$19.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.7M+24.3%	-$6.2M+15.3%	-$7.3M+6.5%	-$7.8M-23.4%	-$6.3M+22.4%	-$8.2M-15.9%	-$7.0M+5.4%	-$7.5M
Capital Expenditures	N/A	N/A	N/A	$0	$0	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	-$7.8M-23.4%	-$6.3M	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	-$215K	$0	N/A	N/A	N/A
Financing Cash Flow	$6.3M+135.7%	$2.7M-46.5%	$5.0M+75.5%	$2.8M-19.8%	$3.5M-71.9%	$12.6M+2.5%	$12.3M+15.2%	$10.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

JAGX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	99.1%+15.9pp	83.3%+4.1pp	79.1%-4.0pp	83.1%+36.9pp	46.2%-18.9pp	65.0%
Operating Margin	-404.9%-141.1pp	-263.8%+87.6pp	-351.3%-63.5pp	-287.8%+651.2pp	-939.0%-655.1pp	-283.9%
Net Margin	-472.5%-472.1pp	-0.3%+0.1pp	-0.4%-0.0pp	-0.4%+0.8pp	-1.2%+359.0pp	-360.3%
Return on Equity	N/A	-0.6%+0.3pp	-0.9%	N/A	-0.4%+196.1pp	-196.5%
Return on Assets	-139.8%-139.7pp	-0.1%+0.0pp	-0.1%+0.0pp	-0.1%0.0pp	-0.1%+78.8pp	-78.9%
Current Ratio	0.50-1.1	1.63-0.4	2.00+1.3	0.74-1.1	1.84+0.5	1.35
Debt-to-Equity	-0.00-6.8	6.84-2.5	9.37+45.3	-35.91-39.4	3.49+2.0	1.49
FCF Margin	-209.0%+42.5pp	-251.5%	N/A	-277.5%+529.3pp	-806.8%-644.0pp	-162.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	82.7%-14.0pp	96.7%+20.0pp	76.7%-7.4pp	84.1%+1.5pp	82.6%-1.7pp	84.3%+2.6pp	81.7%	N/A
Operating Margin	-234.8%+34.0pp	-268.8%+156.7pp	-425.5%-193.1pp	-232.5%+1.2pp	-233.7%+30.8pp	-264.5%+84.9pp	-349.4%	N/A
Net Margin	-308.2%+41.1pp	-349.4%+123.3pp	-472.6%-1285.8pp	813.1%+1130.2pp	-317.1%+31.8pp	-348.8%+43.6pp	-392.4%	N/A
Return on Equity	-218.0%-66.7pp	-151.3%+1109.5pp	-1260.7%-1700.1pp	439.4%+514.6pp	-75.2%-18.0pp	-57.3%+20.8pp	-78.1%	N/A
Return on Assets	-19.2%+2.4pp	-21.6%-1.2pp	-20.3%-73.7pp	53.4%+70.3pp	-16.9%-1.4pp	-15.4%+1.2pp	-16.7%	N/A
Current Ratio	0.81-0.1	0.95-0.1	1.08-0.6	1.63-0.2	1.84-0.3	2.10+0.2	1.89-0.1	2.00
Debt-to-Equity	10.35+4.3	6.02-52.0	58.01+51.2	6.84+3.6	3.27+0.7	2.56-0.9	3.48-5.9	9.37
FCF Margin	N/A	N/A	N/A	-223.0%-19.0pp	-204.0%	N/A	N/A	N/A

Note: Shareholder equity is negative (-$18.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Quoin Pharmaceuticals Ltd QNRX

$11.6M

Xortx Therapeutics Inc XRTX

$3.2M

Azitra Inc AZTR

$3.7M

GRI Bio GRI

$3.5M

Onconetix ONCO

$1.1M

Frequently Asked Questions

What is Jaguar Health Inc's annual revenue?

Jaguar Health Inc (JAGX) reported $11.3M in total revenue for fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Jaguar Health Inc's revenue growing?

Jaguar Health Inc (JAGX) revenue declined by 3% year-over-year, from $11.7M to $11.3M in fiscal year 2025.

Is Jaguar Health Inc profitable?

No, Jaguar Health Inc (JAGX) reported a net income of -$53.6M in fiscal year 2025, with a net profit margin of -472.5%.

What is Jaguar Health Inc's EBITDA?

Jaguar Health Inc (JAGX) had EBITDA of -$44.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Jaguar Health Inc have?

As of fiscal year 2025, Jaguar Health Inc (JAGX) had $968K in cash and equivalents against $52K in long-term debt.

What is Jaguar Health Inc's gross margin?

Jaguar Health Inc (JAGX) had a gross margin of 99.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Jaguar Health Inc's operating margin?

Jaguar Health Inc (JAGX) had an operating margin of -404.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Jaguar Health Inc's net profit margin?

Jaguar Health Inc (JAGX) had a net profit margin of -472.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Jaguar Health Inc's free cash flow?

Jaguar Health Inc (JAGX) generated -$23.7M in free cash flow during fiscal year 2025. This represents a 19.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Jaguar Health Inc's operating cash flow?

Jaguar Health Inc (JAGX) generated -$23.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Jaguar Health Inc's total assets?

Jaguar Health Inc (JAGX) had $38.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Jaguar Health Inc's capital expenditures?

Jaguar Health Inc (JAGX) invested $16K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Jaguar Health Inc spend on research and development?

Jaguar Health Inc (JAGX) invested $25.0M in research and development during fiscal year 2025.

How many shares does Jaguar Health Inc have outstanding?

Jaguar Health Inc (JAGX) had 13M shares outstanding as of fiscal year 2025.

What is Jaguar Health Inc's current ratio?

Jaguar Health Inc (JAGX) had a current ratio of 0.50 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Jaguar Health Inc's debt-to-equity ratio?

Jaguar Health Inc (JAGX) had a debt-to-equity ratio of -0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Jaguar Health Inc's return on assets (ROA)?

Jaguar Health Inc (JAGX) had a return on assets of -139.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Jaguar Health Inc's cash runway?

Based on fiscal year 2025 data, Jaguar Health Inc (JAGX) had $968K in cash against an annual operating cash burn of $23.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Jaguar Health Inc's debt-to-equity ratio negative or unusual?

Jaguar Health Inc (JAGX) has negative shareholder equity of -$18.7M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Jaguar Health Inc's Piotroski F-Score?

Jaguar Health Inc (JAGX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Jaguar Health Inc's earnings high quality?

Jaguar Health Inc (JAGX) has an earnings quality ratio of 0.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Jaguar Health Inc cover its interest payments?

Jaguar Health Inc (JAGX) has an interest coverage ratio of -685.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Jaguar Health Inc?

Jaguar Health Inc (JAGX) scores 8 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.